- According to a US-based study, children ages 5 to 11 who received the Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine were 68% less likely to be hospitalized during the omicron wave than unvaccinated children.
- Adolescents aged 12-18 who received two shots of the vaccine were around 40% less likely to be hospitalized with the Omicron variant of the virus.
- The study was led by scientists from the U.S. Centers for Disease Control and Prevention (CDC) and Boston Children's Hospital.
- It was published in the New England Journal of Medicine.
- Related: Pfizer-BioNTech's COVID-19 Shot Moderately Effective Against Omicron In Kids Aged 5 to 15, CDC Study Shows.
- The risk of more serious outcomes, including the need for mechanical breathing assistance or death, was nearly 80% lower for those who received the shots in that age group.
- The study found that vaccine effectiveness against hospitalization in adolescents when that variant was dominant was around 93% against the Delta variant.
- Also See: Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6.
- Price Action: PFE shares are down 0.90% at $51.97during the market session on the last check Thursday.
- Photo by X3 via Pixaby
